Comparative Pharmacology
Head-to-head clinical analysis: AZASITE versus ERYC 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZASITE versus ERYC 125.
AZASITE vs ERYC 125
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It also activates motilin receptors in the gastrointestinal tract, enhancing gastric motility.
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
1.5-2.0 hours in adults; prolonged in hepatic impairment (up to 5-6 hours) or neonates.
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
Primarily hepatic metabolism; ~2-5% excreted unchanged in urine, ~15-20% in bile/feces as active drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic